"Double-Blind Method" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
| Descriptor ID |
D004311
|
| MeSH Number(s) |
E05.318.780.300 E05.581.500.300 N05.715.360.780.320 N06.850.520.445.300
|
| Concept/Terms |
Double-Blind Method- Double-Blind Method
- Double Blind Method
- Double-Blind Methods
- Method, Double-Blind
- Methods, Double-Blind
- Double-Masked Method
- Double Masked Method
- Double-Masked Methods
- Method, Double-Masked
- Methods, Double-Masked
- Double-Masked Study
- Double Masked Study
- Double-Masked Studies
- Studies, Double-Masked
- Study, Double-Masked
- Double-Blind Study
- Double Blind Study
- Double-Blind Studies
- Studies, Double-Blind
- Study, Double-Blind
|
Below are MeSH descriptors whose meaning is more general than "Double-Blind Method".
Below are MeSH descriptors whose meaning is more specific than "Double-Blind Method".
This graph shows the total number of publications written about "Double-Blind Method" by people in this website by year, and whether "Double-Blind Method" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 6 | 6 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 5 | 5 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 4 | 4 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 6 | 6 |
| 2010 | 0 | 9 | 9 |
| 2011 | 0 | 5 | 5 |
| 2012 | 0 | 11 | 11 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 10 | 10 |
| 2015 | 0 | 8 | 8 |
| 2016 | 0 | 9 | 9 |
| 2017 | 0 | 9 | 9 |
| 2018 | 0 | 11 | 11 |
| 2019 | 0 | 11 | 11 |
| 2020 | 0 | 16 | 16 |
| 2021 | 0 | 10 | 10 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 6 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Double-Blind Method" by people in Profiles.
-
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. J Infect Dis. 2024 Aug 16; 230(2):e405-e415.
-
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702. Vaccine. 2024 Aug 13; 42(20):125991.
-
Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials. Diabetes Obes Metab. 2024 Aug; 26(8):3223-3237.
-
Influence of vitamin D supplementation on bone mineral content, bone turnover markers, and fracture risk in South African schoolchildren: multicenter double-blind randomized placebo-controlled trial (ViDiKids). J Bone Miner Res. 2024 Apr 19; 39(3):211-221.
-
Influence of vitamin D supplementation on growth, body composition, pubertal development and spirometry in South African schoolchildren: a randomised controlled trial (ViDiKids). BMJ Paediatr Open. 2024 Apr 10; 8(1).
-
Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment. Eur J Prev Cardiol. 2024 Feb 15; 31(3):302-310.
-
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20; 388(16):1451-1464.
-
Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther. 2024 Jun; 38(3):493-503.
-
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT. Lancet Diabetes Endocrinol. 2022 10; 10(10):732-740.
-
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial. Lancet Infect Dis. 2022 Oct; 22(10):1472-1483.